EconDefense
ACQ-55 / Intellectual property and technology transfer

Retain licensing royalties and reinvest in inventors and laboratory missions

Retain laboratory invention licensing receipts, reward inventors and eligible contributors, and reinvest statutory balances in technology transfer, workforce and mission research.

Authority / instrument · ACQ-55

Technology transfer

Intellectual property and technology transfer

Statute & instrument
Authority holder

Agency or laboratory head and designated distribution officials

What this does not authorize / hard limit

Not unrestricted profit retention: residual amounts, excess-receipt shares and expired balances go to Treasury.

Recorded executor

Laboratory ORTA, counsel and authorized agreement official

Continue to actor →

Recorded executing role; this record-specific route is not an additional institutional office.

Legal basisSources linkedLegal sources and instrument limits are recorded.
RequirementsGates recordedRead the requirements for this instrument; applicability depends on the proposed action.
Public fundingRules recordedBalance generally available in receipt year and two succeeding fiscal years; statutory inventor share and distribution rules precede reinvestment. Office budget figures are separate institutional context, not an allocation to this instrument.
Assigned rolesRoles recordedPublic sources describe institutional authority. The instrument identifies approval and execution roles; a specific signature remains transaction-dependent.
EngagementRelated evidenceIdentify the actual royalty administrator while keeping internal receipts distinct from external financing. Program check: 2026-10-04; see each route for intake status.

Public evidence describes the institution and instrument; it is not approval of an individual transaction.

At a glance

Possible toolACQ-55 · Licensing & IP

Authority holder: Agency or laboratory head and designated distribution officials

Licensing & IP

Mechanism tags describe the source text; they do not expand the authority.

Availability and verification

Express statutory pathway; award-specific appropriations, available balances, delegations, implementation and approvals not independently verified.

Program process and intake

Checked 2026-10-04 · process documented. Program evidence is separate from legal authority, available funds and transaction approval.

Identify the actual royalty administrator while keeping internal receipts distinct from external financing.

DAF patent royalty administration

Who this route serves
Federal inventors, laboratories and royalty administrators; not outside grant applicants
Administering office / routing lead
DAF Technology Transfer and Transition program office and responsible laboratory
Related process

Operational responsibility for royalty disbursement is documented; the statute, not the office description, controls distribution and permitted uses.

What this evidence label means
Internal administration documented

The published process was checked; no award or appointment availability is inferred.

Status reference date: 2026-10-04 · research checked 2026-10-04

DAF Technology Transfer program office · Overview; institutional contact detailsofficial program guidance · Evidence record

Program eligibility

  • The DAF program office expressly oversees and issues patent royalty disbursements. This is an internal administration route, not a business funding application.

    DAF Technology Transfer program office · Overview; institutional contact detailsofficial program guidance · Evidence record

Steps and preparation

  • Use the responsible laboratory and DAF T3 royalty administrators to establish receipt attribution and disbursement treatment. This routing recommendation follows the office’s published remit.

    DAF Technology Transfer program office · Overview; institutional contact detailsofficial program guidance · Evidence record
Funding, limits and authority relationship

Funding and financial terms

  • Retained licensing receipts · Receipt-year statutory rules; historical source edition

    The cited 2024 statutory edition governs sharing and permitted retention of licensing receipts; it does not create an independently funded grant pool.

    15 USC 3710c, 2024 edition · Royalty distribution and retained receipts; historical statutory editionhistorical statutory edition · Evidence record

Exclusions and limits

Authority relationship source

DAF Technology Transfer program office · Overview; institutional contact detailsofficial program guidance · Evidence record

Read the official process →

program information: Information and institutional inquiry, not an award application.

Research scope and sources checked

The first program-depth pass checked the cited program pages, notices and legal framework. Evidence is limited to the named routes and source-access notes; it does not establish every implementation of the statute.

What remains unverified

  • No public DAF-wide current balance, inventor-specific entitlement or detailed disbursement form was verified.

A dated source check is not continuing monitoring. Recheck the linked official notice before preparing a submission. Browse program research →

Requirements and limits

Eligibility & prerequisites

  • Receipts must arise from covered invention licensing/assignment; required inventor distribution and permitted-use rules.

Limits & exclusions

  • Not unrestricted profit retention: residual amounts, excess-receipt shares and expired balances go to Treasury.
  • Individual annual reward ceiling and Presidential exception apply.

Funding conditions

  • Balance generally available in receipt year and two succeeding fiscal years; statutory inventor share and distribution rules precede reinvestment.

Read the funding and execution guide

Who contributes what

Need & planning

  • Laboratory scientific lead and Office of Research and Technology Applications

Resources

  • Laboratory director and sponsoring component budget owner

Approval

  • Laboratory director and agency approver as statute/delegation requires

Execution

  • Laboratory ORTA, counsel and authorized agreement official

Partners & review

  • Industry, universities, nonprofit and government collaborators within eligibility limits

Office links are editorial matches to the original role text, not verified delegations. Composite labels and unmatched actors are preserved.

Coordination pathway

ORTA/license administrator collects royalties → agency/lab fiscal officials distribute statutory shares → director funds eligible mission activities → return required balances.

Actor and execution-role sources

What this research establishes

Legal basisSources linkedLegal sources and instrument limits are recorded.
RequirementsGates recordedRead the requirements for this instrument; applicability depends on the proposed action.
Public fundingRules recordedBalance generally available in receipt year and two succeeding fiscal years; statutory inventor share and distribution rules precede reinvestment. Office budget figures are separate institutional context, not an allocation to this instrument.
Assigned rolesRoles recordedPublic sources describe institutional authority. The instrument identifies approval and execution roles; a specific signature remains transaction-dependent.
EngagementRelated evidenceIdentify the actual royalty administrator while keeping internal receipts distinct from external financing. Program check: 2026-10-04; see each route for intake status.

Confidence: High on express authority and cited conditions; execution assignment is illustrative unless statute expressly names it.

Currentness: GovInfo 2024 Code (includes FY2025 NDAA, P.L. 118-159) read in full for cited provision; targeted FY2026 NDAA P.L. 119-60 amendment/repeal sweep. No claim of complete legislative currency through 2026-10-02; remaining 2026 delta needs counsel validation.

Review scope: Original research target October 2, 2026; no record-specific last-review date supplied. Publication is not legal-currentness certification.